Skip to main content
GE enters licensing deal on asymptomatic malaria detection

GE, the Global Good Fund and Access Bio will make and distribute rapid diagnostic technologies for asymptomatic malaria detection in low-resource countries under a licensing deal. The agreement also covers a technology that supports the creation of malarial serology tests for Plasmodium antibodies, as well as Plasmodium lactate dehydrogenase rapid diagnostic tests for malarial parasite detection and a highly sensitive diagnostic test for identification of malaria-related proteins.

Full Story: